|
CN102604957B
(zh)
*
|
2003-06-11 |
2015-10-07 |
艾德拉药物股份有限公司 |
稳定的免疫调节寡核苷酸
|
|
MXPA06000619A
(es)
*
|
2003-07-15 |
2006-04-11 |
Hybridon Inc |
Estimulacion sinergistica del sistema inmune usando oligonucleotidos inmunoestimuladores y/o compuestos inmunomeros en conjunto con citocinas y/o agentes quimioterapeuticos o terapia de radiacion.
|
|
AU2004275876B2
(en)
*
|
2003-09-25 |
2011-03-31 |
Coley Pharmaceutical Gmbh |
Nucleic acid-lipophilic conjugates
|
|
AU2005282889B2
(en)
|
2004-09-01 |
2012-03-15 |
Dynavax Technologies Corporation |
Methods and conpositions for inhibition of innate immune responses and autoimmunity
|
|
EP4082551A1
(en)
|
2006-08-08 |
2022-11-02 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Structure and use of 5' phosphate oligonucleotides
|
|
JP5737937B2
(ja)
*
|
2007-07-09 |
2015-06-17 |
イデラ ファーマシューティカルズ インコーポレイテッドＩｄｅｒａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
安定化免疫調節ｒｎａ（ｓｉｍｒａ）化合物
|
|
CA2703931C
(en)
|
2007-10-26 |
2016-08-16 |
Dynavax Technologies Corporation |
Methods and compositions for inhibition of immune responses and autoimmunity
|
|
JP5753382B2
(ja)
*
|
2007-11-06 |
2015-07-22 |
アディウティーダ ファーマシューティカルズ ゲーエムベーハー |
修飾されたオリゴリン酸基を含有する免疫賦活オリゴリボヌクレオチドアナログ
|
|
EP2297323A1
(en)
|
2008-05-21 |
2011-03-23 |
Hartmann, Gunther |
5' triphosphate oligonucleotide with blunt end and uses thereof
|
|
WO2010093705A2
(en)
*
|
2009-02-10 |
2010-08-19 |
Idera Pharmaceuticals, Inc. |
Synthetic rna-based agonists of tlr7
|
|
KR101141544B1
(ko)
|
2009-03-13 |
2012-05-03 |
한국과학기술원 |
에스아이알엔에이 다중 접합체 및 이의 제조방법
|
|
ES2534947T3
(es)
|
2009-03-25 |
2015-04-30 |
The Board Of Regents Of The University Of Texas System |
Composiciones para la estimulación de resistencia inmunitaria innata de mamíferos a patógenos
|
|
HRP20150566T1
(hr)
*
|
2009-08-27 |
2015-07-17 |
Idera Pharmaceuticals, Inc. |
Kompozicija za inhibiciju ekspresije gena i njegova upotreba
|
|
US8940310B2
(en)
|
2010-06-16 |
2015-01-27 |
Dynavax Technologies Corporation |
Methods of treatment using TLR7 and/or TLR9 inhibitors
|
|
US8492358B2
(en)
*
|
2010-06-25 |
2013-07-23 |
Idera Pharmaceuticals, Inc. |
Agonists of toll-like receptor 3 and methods of their use
|
|
US8877722B2
(en)
|
2011-03-25 |
2014-11-04 |
Idera Pharmaceuticals, Inc. |
Compositions for inhibiting gene expression and uses thereof
|
|
EP2508530A1
(en)
|
2011-03-28 |
2012-10-10 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Purification of triphosphorylated oligonucleotides using capture tags
|
|
US9844592B2
(en)
|
2011-07-18 |
2017-12-19 |
Icahn School Of Medicine At Mount Sinai |
Bacterial RNAs as vaccine adjuvants
|
|
HK1200191A1
(en)
|
2011-11-18 |
2015-07-31 |
Alnylam Pharmaceuticals, Inc. |
Modified rnai agents
|
|
WO2013075035A1
(en)
|
2011-11-18 |
2013-05-23 |
Alnylam Pharmaceuticals |
Rnai agents, compositions and methods of use thereof for treating transthyretin (ttr) associated diseases
|
|
DK2812434T3
(en)
*
|
2012-02-09 |
2018-07-16 |
Bavarian Nordic As |
AGONISTS AND ANTAGONISTS OF TOLL-LIKE RECEPTOR-13 (TLR-13)
|
|
CA2879683C
(en)
|
2012-08-03 |
2023-02-14 |
Alnylam Pharmaceuticals, Inc. |
Modified rnai agents
|
|
EP2712870A1
(en)
|
2012-09-27 |
2014-04-02 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Novel RIG-I ligands and methods for producing them
|
|
US9868955B2
(en)
|
2012-09-29 |
2018-01-16 |
Dynavax Technologies Corporation |
Human toll-like receptor inhibitors and methods of use thereof
|
|
US9228184B2
(en)
|
2012-09-29 |
2016-01-05 |
Dynavax Technologies Corporation |
Human toll-like receptor inhibitors and methods of use thereof
|
|
PT2929031T
(pt)
|
2012-12-05 |
2018-01-19 |
Alnylam Pharmaceuticals Inc |
Composições de irna de pcsk9 e métodos de seu uso
|
|
WO2014110081A1
(en)
*
|
2013-01-08 |
2014-07-17 |
Idera Pharmaceuticals, Inc. |
Immune regulatory oligonucleotide (iro) compounds to modulate toll-like receptor based immune response
|
|
CN114015692B
(zh)
|
2013-03-14 |
2024-12-31 |
阿尔尼拉姆医药品有限公司 |
补体组分C5 iRNA组合物及其使用方法
|
|
EP3412774A1
(en)
|
2013-05-22 |
2018-12-12 |
Alnylam Pharmaceuticals, Inc. |
Serpina1 irna compositions and methods of use thereof
|
|
TWI727917B
(zh)
|
2013-05-22 |
2021-05-21 |
美商阿尼拉製藥公司 |
ＴＭＰＲＳＳ６ｉＲＮＡ 組成物及其使用方法
|
|
TW201610151A
(zh)
|
2013-09-23 |
2016-03-16 |
阿尼拉製藥公司 |
治療或預防與甲狀腺素運載蛋白相關疾病之方法
|
|
IL314045A
(en)
|
2013-12-12 |
2024-09-01 |
Alnylam Pharmaceuticals Inc |
Complement component irna compositions and methods of use thereof
|
|
US10119136B2
(en)
|
2014-01-09 |
2018-11-06 |
Alnylam Pharmaceuticals, Inc. |
RNAi agents modified at the 4′-C position
|
|
KR102592370B1
(ko)
|
2014-02-11 |
2023-10-25 |
알닐람 파마슈티칼스 인코포레이티드 |
케토헥소키나제(ＫＨＫ) ｉＲＮＡ 조성물 및 그의 사용 방법
|
|
TW201607559A
(zh)
|
2014-05-12 |
2016-03-01 |
阿尼拉製藥公司 |
治療ｓｅｒｐｉｎｃ１相關疾患之方法和組成物
|
|
MX382901B
(es)
|
2014-05-22 |
2025-03-13 |
Alnylam Pharmaceuticals Inc |
Composiciones de angiotensinogeno (agt) arni y métodos de uso de las mismas.
|
|
IL316808A
(en)
|
2014-08-20 |
2025-01-01 |
Alnylam Pharmaceuticals Inc |
Modified double-stranded RNA materials and their uses
|
|
WO2016044839A2
(en)
|
2014-09-19 |
2016-03-24 |
The Board Of Regents Of The University Of Texas System |
Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
|
|
TWI755351B
(zh)
|
2014-10-10 |
2022-02-21 |
美商艾爾妮蘭製藥公司 |
用於抑制ｈａｏ１（羥酸氧化酶１（乙醇酸鹽氧化酶））基因表現的組合物及方法
|
|
JOP20200092A1
(ar)
|
2014-11-10 |
2017-06-16 |
Alnylam Pharmaceuticals Inc |
تركيبات iRNA لفيروس الكبد B (HBV) وطرق لاستخدامها
|
|
CN107250362B
(zh)
|
2014-11-17 |
2021-10-22 |
阿尔尼拉姆医药品有限公司 |
载脂蛋白C3(APOC3)iRNA组合物及其使用方法
|
|
US20170369872A1
(en)
|
2014-12-18 |
2017-12-28 |
Alnylam Pharmaceuticals, Inc. |
Reversir tm compounds
|
|
JP2018510621A
(ja)
|
2015-02-13 |
2018-04-19 |
アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
パタチン様ホスホリパーゼドメイン含有３（ＰＮＰＬＡ３）ｉＲＮＡ組成物およびその使用方法
|
|
WO2016201301A1
(en)
|
2015-06-12 |
2016-12-15 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions and methods of use thereof
|
|
IL316159A
(en)
|
2015-06-15 |
2024-12-01 |
Mpeg La Llc |
Defined Oligonucleotide Multimers and Methods for Manufacture Thereof
|
|
DE102015008536A1
(de)
|
2015-07-02 |
2017-01-05 |
Rheinische Friedrich-Wilhelms-Universität Bonn |
Diskontinuierliche Oligonukleotid-Liganden
|
|
WO2017011286A1
(en)
|
2015-07-10 |
2017-01-19 |
Alnylam Pharmaceuticals, Inc. |
Insulin-like growth factor binding protein, acid labile subunit (igfals) and insulin-like growth factor 1 (igf-1) irna compositions and methods of use thereof
|
|
SG10202007937SA
(en)
|
2015-09-02 |
2020-09-29 |
Alnylam Pharmaceuticals Inc |
PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
|
CN107206104A
(zh)
*
|
2015-11-13 |
2017-09-26 |
擎新（厦门）生物科技有限公司 |
基于微小RNA miR‑574‑5p的化合物作为免疫调节剂的用途及它们的组合物
|
|
KR20210157474A
(ko)
|
2015-12-07 |
2021-12-28 |
젠자임 코포레이션 |
Serpinc1-연관 장애의 치료를 위한 방법 및 조성물
|
|
WO2017136399A1
(en)
*
|
2016-02-02 |
2017-08-10 |
Idera Pharmaceuticals, Inc. |
POTENTIATION OF mmRNA THERAPEUTICS
|
|
EP3469083A1
(en)
|
2016-06-10 |
2019-04-17 |
Alnylam Pharmaceuticals, Inc. |
COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
|
|
CN106119357B
(zh)
*
|
2016-06-29 |
2019-09-10 |
北京泱深生物信息技术有限公司 |
Tns11在制备诊治子宫内膜癌产品中的应用
|
|
TW202313978A
(zh)
|
2016-11-23 |
2023-04-01 |
美商阿尼拉製藥公司 |
絲胺酸蛋白酶抑制因子Ａ１ ｉＲＮＡ組成物及其使用方法
|
|
SG10201913552UA
(en)
|
2016-12-16 |
2020-03-30 |
Alnylam Pharmaceuticals Inc |
Methods for treating or preventing ttr-associated diseases using transthyretin (ttr) irna compositions
|
|
US11364259B2
(en)
*
|
2016-12-27 |
2022-06-21 |
The University Of Tokyo |
MRNA functionalization method
|
|
MX2019009347A
(es)
|
2017-02-06 |
2019-10-07 |
Mpeg La Llc |
Oligonucleotidos multimericos con menor eliminacion en el riñon.
|
|
US20200163987A1
(en)
|
2017-07-10 |
2020-05-28 |
Genzyme Corporation |
Methods and compositions for treating a bleeding event in a subject having hemophilia
|
|
JP7277432B2
(ja)
|
2017-07-13 |
2023-05-19 |
アルナイラム ファーマシューティカルズ， インコーポレイテッド |
乳酸脱水素酵素Ａ（ＬＤＨＡ）ｉＲＮＡ組成物及びその使用方法
|
|
US20200385719A1
(en)
|
2017-11-16 |
2020-12-10 |
Alnylam Pharmaceuticals, Inc. |
Kisspeptin 1 (kiss1) irna compositions and methods of use thereof
|
|
WO2019100039A1
(en)
|
2017-11-20 |
2019-05-23 |
Alnylam Pharmaceuticals, Inc. |
Serum amyloid p component (apcs) irna compositions and methods of use thereof
|
|
BR112020012088A2
(pt)
|
2017-12-18 |
2020-11-17 |
Alnylam Pharmaceuticals, Inc. |
composições de irna do grupo de elevada mobilidade box-1 (hmgb1) e métodos de uso dos mesmos
|
|
MX2020011570A
(es)
|
2018-05-07 |
2020-11-24 |
Alnylam Pharmaceuticals Inc |
Administracion extrahepatica.
|
|
TWI851574B
(zh)
|
2018-05-14 |
2024-08-11 |
美商阿尼拉製藥公司 |
血管收縮素原（ＡＧＴ）ｉＲＮＡ組成物及其使用方法
|
|
US20210332367A1
(en)
|
2018-09-18 |
2021-10-28 |
Alnylam Pharmaceuticals, Inc. |
KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
|
WO2020069055A1
(en)
|
2018-09-28 |
2020-04-02 |
Alnylam Pharmaceuticals, Inc. |
Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated ocular diseases
|
|
AU2020279101B2
(en)
|
2019-05-17 |
2025-07-24 |
Alnylam Pharmaceuticals, Inc. |
Oral delivery of oligonucleotides
|
|
WO2021022109A1
(en)
|
2019-08-01 |
2021-02-04 |
Alnylam Pharmaceuticals, Inc. |
SERPIN FAMILY F MEMBER 2 (SERPINF2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
|
WO2021022108A2
(en)
|
2019-08-01 |
2021-02-04 |
Alnylam Pharmaceuticals, Inc. |
CARBOXYPEPTIDASE B2 (CPB2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
|
WO2021030522A1
(en)
|
2019-08-13 |
2021-02-18 |
Alnylam Pharmaceuticals, Inc. |
SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
|
|
EP4038189A1
(en)
|
2019-10-04 |
2022-08-10 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing ugt1a1 gene expression
|
|
US12486512B2
(en)
|
2019-10-18 |
2025-12-02 |
Alnylam Pharmaceuticals, Inc. |
Solute carrier family member iRNA compositions and methods of use thereof
|
|
AU2020369515A1
(en)
|
2019-10-22 |
2022-04-21 |
Alnylam Pharmaceuticals, Inc. |
Complement component C3 iRNA compositions and methods of use thereof
|
|
WO2021087325A1
(en)
|
2019-11-01 |
2021-05-06 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing dnajb1-prkaca fusion gene expression
|
|
CN119499394A
(zh)
|
2019-11-01 |
2025-02-25 |
阿尔尼拉姆医药品有限公司 |
亨廷顿（HTT）iRNA药剂组合物及其使用方法
|
|
EP4055165A1
(en)
|
2019-11-06 |
2022-09-14 |
Alnylam Pharmaceuticals, Inc. |
Transthyretin (ttr) irna compositions and methods of use thereof for treating or preventing ttr-associated ocular diseases
|
|
EP4055166A2
(en)
|
2019-11-06 |
2022-09-14 |
Alnylam Pharmaceuticals, Inc. |
Extrahepatic delivery
|
|
TWI877247B
(zh)
|
2019-11-13 |
2025-03-21 |
美商阿尼拉製藥公司 |
用於治療血管收縮素原相關病症之方法及組成物
|
|
WO2021102373A1
(en)
|
2019-11-22 |
2021-05-27 |
Alnylam Pharmaceuticals, Inc. |
Ataxin3 (atxn3) rnai agent compositions and methods of use thereof
|
|
PH12022551394A1
(en)
|
2019-12-13 |
2023-09-11 |
Alnylam Pharmaceuticals Inc |
Human chromosome 9 open reading frame 72 (c9orf72) irna agent compositions and methods of use thereof
|
|
TW202138559A
(zh)
|
2019-12-16 |
2021-10-16 |
美商阿尼拉製藥公司 |
含類ＰＡＴＡＴＩＮ磷脂酶結構域３（ＰＮＰＬＡ３）ｉＲＮＡ組成物及其使用方法
|
|
WO2021154941A1
(en)
|
2020-01-31 |
2021-08-05 |
Alnylam Pharmaceuticals, Inc. |
Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
|
|
AU2021220765A1
(en)
|
2020-02-10 |
2022-09-01 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing VEGF-A expression
|
|
JP7735288B2
(ja)
|
2020-02-18 |
2025-09-08 |
アルナイラム ファーマシューティカルズ， インコーポレイテッド |
アポリポタンパク質Ｃ３（ＡＰＯＣ３）ｉＲＮＡ組成物およびその使用法
|
|
EP4114947A1
(en)
|
2020-03-05 |
2023-01-11 |
Alnylam Pharmaceuticals, Inc. |
Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases
|
|
WO2021178736A1
(en)
|
2020-03-06 |
2021-09-10 |
Alnylam Pharmaceuticals, Inc. |
KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
|
WO2021188611A1
(en)
|
2020-03-18 |
2021-09-23 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for treating subjects having a heterozygous alanine-glyoxylate aminotransferase gene (agxt) variant
|
|
WO2021195307A1
(en)
|
2020-03-26 |
2021-09-30 |
Alnylam Pharmaceuticals, Inc. |
Coronavirus irna compositions and methods of use thereof
|
|
US20230190785A1
(en)
|
2020-03-30 |
2023-06-22 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing dnajc15 gene expression
|
|
EP4127134A4
(en)
|
2020-04-01 |
2024-07-31 |
Alnylam Pharmaceuticals, Inc. |
COMPOSITIONS OF ALPHA-2A ADRENERGIC RECEPTOR (ADRA2A) ARNI AGENTS AND METHODS OF USE THEREOF
|
|
AR121769A1
(es)
|
2020-04-06 |
2022-07-06 |
Alnylam Pharmaceuticals Inc |
Composiciones y métodos para el silenciamiento de la expresión de myoc
|
|
CA3179678A1
(en)
|
2020-04-07 |
2021-10-14 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for silencing scn9a expression
|
|
EP4133076A1
(en)
|
2020-04-07 |
2023-02-15 |
Alnylam Pharmaceuticals, Inc. |
Angiotensin-converting enzyme 2 (ace2) irna compositions and methods of use thereof
|
|
WO2021206922A1
(en)
|
2020-04-07 |
2021-10-14 |
Alnylam Pharmaceuticals, Inc. |
Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof
|
|
KR20230018377A
(ko)
|
2020-04-27 |
2023-02-07 |
알닐람 파마슈티칼스 인코포레이티드 |
아포지질단백질 e (apoe) irna 제제 조성물 및 이의 사용 방법
|
|
BR112022021136A2
(pt)
|
2020-04-30 |
2022-11-29 |
Alnylam Pharmaceuticals Inc |
Composições de irna de fator b de complemento (cfb) e métodos de uso das mesmas
|
|
JP2023526090A
(ja)
*
|
2020-05-19 |
2023-06-20 |
ハドソン インスティチュート オブ メディカル リサーチ |
オリゴヌクレオチド
|
|
EP4153746A1
(en)
|
2020-05-21 |
2023-03-29 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting marc1 gene expression
|
|
EP3919076A1
(en)
|
2020-06-02 |
2021-12-08 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Synthetic oligosaccharide vaccines against streptococcus pneumoniae with microparticle adjuvant formulations
|
|
EP4162050A1
(en)
|
2020-06-09 |
2023-04-12 |
Alnylam Pharmaceuticals, Inc. |
Rnai compositions and methods of use thereof for delivery by inhalation
|
|
JP2023529903A
(ja)
|
2020-06-09 |
2023-07-12 |
アルナイラム ファーマシューティカルズ， インコーポレイテッド |
ＧＰＡＭ（グリセロール－３－リン酸アシルトランスフェラーゼ１、ミトコンドリア）発現をサイレンシングするためのｓｉＲＮＡ組成物および方法
|
|
TW202214856A
(zh)
|
2020-06-18 |
2022-04-16 |
美商阿尼拉製藥公司 |
黃嘌呤脫氫酶（ＸＤＨ）ｉＲＮＡ組成物及其使用之方法
|
|
US20230257745A1
(en)
|
2020-07-10 |
2023-08-17 |
Alnylam Pharmaceuticals, Inc. |
Circular siRNAs
|
|
WO2022066847A1
(en)
|
2020-09-24 |
2022-03-31 |
Alnylam Pharmaceuticals, Inc. |
Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof
|
|
WO2022076291A1
(en)
|
2020-10-05 |
2022-04-14 |
Alnylam Pharmaceuticals, Inc. |
G protein-coupled receptor 75 (gpr75) irna compositions and methods of use thereof
|
|
CA3198823A1
(en)
|
2020-10-21 |
2022-04-28 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating primary hyperoxaluria
|
|
WO2022087329A1
(en)
|
2020-10-23 |
2022-04-28 |
Alnylam Pharmaceuticals, Inc. |
Mucin 5b (muc5b) irna compositions and methods of use thereof
|
|
IL302709A
(en)
|
2020-11-13 |
2023-07-01 |
Alnylam Pharmaceuticals Inc |
Coagulation factor iRNA compositions (F5) and methods of using them
|
|
AU2021393417A1
(en)
|
2020-12-01 |
2023-06-29 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
|
|
EP4259795A1
(en)
|
2020-12-08 |
2023-10-18 |
Alnylam Pharmaceuticals, Inc. |
Coagulation factor x (f10) irna compositions and methods of use thereof
|
|
WO2022147223A2
(en)
|
2020-12-31 |
2022-07-07 |
Alnylam Pharmaceuticals, Inc. |
2'-modified nucleoside based oligonucleotide prodrugs
|
|
AU2021411579A1
(en)
|
2020-12-31 |
2023-07-13 |
Alnylam Pharmaceuticals, Inc. |
Cyclic-disulfide modified phosphate based oligonucleotide prodrugs
|
|
EP4274896A1
(en)
|
2021-01-05 |
2023-11-15 |
Alnylam Pharmaceuticals, Inc. |
Complement component 9 (c9) irna compositions and methods of use thereof
|
|
EP4291654A2
(en)
|
2021-02-12 |
2023-12-20 |
Alnylam Pharmaceuticals, Inc. |
Superoxide dismutase 1 (sod1) irna compositions and methods of use thereof for treating or preventing superoxide dismutase 1- (sod1-) associated neurodegenerative diseases
|
|
JP2024509783A
(ja)
|
2021-02-25 |
2024-03-05 |
アルナイラム ファーマシューティカルズ， インコーポレイテッド |
プリオンタンパク質（ｐｒｎｐ）ｉｒｎａ組成物およびその使用方法
|
|
AU2022226098A1
(en)
|
2021-02-26 |
2023-08-24 |
Alnylam Pharmaceuticals, Inc. |
KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
|
|
IL305418A
(en)
|
2021-03-04 |
2023-10-01 |
Alnylam Pharmaceuticals Inc |
Angiopoietin-like 3 (ANGPTL3) IRNA compositions and methods of using them
|
|
EP4305169A1
(en)
|
2021-03-12 |
2024-01-17 |
Alnylam Pharmaceuticals, Inc. |
Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof
|
|
MX2023011466A
(es)
|
2021-03-29 |
2024-02-01 |
Alnylam Pharmaceuticals Inc |
Composiciones de agentes de ácido ribonucleico de interferencia (arni) de huntingtina (htt) y métodos de uso de estas.
|
|
WO2022212153A1
(en)
|
2021-04-01 |
2022-10-06 |
Alnylam Pharmaceuticals, Inc. |
Proline dehydrogenase 2 (prodh2) irna compositions and methods of use thereof
|
|
TW202309280A
(zh)
|
2021-04-26 |
2023-03-01 |
美商艾拉倫製藥股份有限公司 |
跨膜絲胺酸蛋白酶６（ＴＭＰＲＳＳ６）ｉＲＮＡ組成物及其使用方法
|
|
EP4330396A1
(en)
|
2021-04-29 |
2024-03-06 |
Alnylam Pharmaceuticals, Inc. |
Signal transducer and activator of transcription factor 6 (stat6) irna compositions and methods of use thereof
|
|
EP4341401A1
(en)
|
2021-05-18 |
2024-03-27 |
Alnylam Pharmaceuticals, Inc. |
Sodium-glucose cotransporter-2 (sglt2) irna compositions and methods of use thereof
|
|
EP4347823A1
(en)
|
2021-06-02 |
2024-04-10 |
Alnylam Pharmaceuticals, Inc. |
Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
|
|
TW202308663A
(zh)
|
2021-06-04 |
2023-03-01 |
美商艾拉倫製藥股份有限公司 |
人類染色體９開讀框７２（Ｃ９ＯＲＦ７２）ｉＲＮＡ劑組成物及其使用方法
|
|
EP4351541A2
(en)
|
2021-06-08 |
2024-04-17 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for treating or preventing stargardt's disease and/or retinal binding protein 4 (rbp4)-associated disorders
|
|
AU2022303164A1
(en)
|
2021-06-30 |
2024-01-18 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating an angiotensinogen- (agt-) associated disorder
|
|
JP2024527584A
(ja)
|
2021-07-09 |
2024-07-25 |
アルナイラム ファーマシューティカルズ， インコーポレイテッド |
ＣＮＳ送達のためのＢｉｓ－ＲＮＡｉ化合物
|
|
JP2024528659A
(ja)
|
2021-07-19 |
2024-07-30 |
アルナイラム ファーマシューティカルズ， インコーポレイテッド |
非原発性高シュウ酸尿症疾患または障害を有するまたは発症するリスクがある対象を治療するための方法および組成物
|
|
CA3226887A1
(en)
|
2021-07-21 |
2023-01-26 |
Alnylam Pharmaceuticals, Inc. |
Metabolic disorder-associated target gene irna compositions and methods of use thereof
|
|
TW202325312A
(zh)
|
2021-07-23 |
2023-07-01 |
美商艾拉倫製藥股份有限公司 |
β－鏈蛋白（ＣＴＮＮＢ１）ｉＲＮＡ組成物及其使用方法
|
|
EP4377458A1
(en)
|
2021-07-29 |
2024-06-05 |
Alnylam Pharmaceuticals, Inc. |
3-hydroxy-3-methylglutaryl-coa reductase (hmgcr) irna compositions and methods of use thereof
|
|
CA3227852A1
(en)
|
2021-08-03 |
2023-02-09 |
Alnylam Pharmaceuticals, Inc. |
Transthyretin (ttr) irna compositions and methods of use thereof
|
|
AU2022324003A1
(en)
|
2021-08-04 |
2024-02-08 |
Alnylam Pharmaceuticals, Inc. |
iRNA COMPOSITIONS AND METHODS FOR SILENCING ANGIOTENSINOGEN (AGT)
|
|
MX2024001573A
(es)
|
2021-08-13 |
2024-02-14 |
Alnylam Pharmaceuticals Inc |
Composiciones de acido ribonucleico de interferencia (arni) contra el factor xii (f12) y sus metodos de uso.
|
|
JP2024538859A
(ja)
|
2021-08-31 |
2024-10-24 |
アルナイラム ファーマシューティカルズ， インコーポレイテッド |
細胞死誘導ＤＦＦＡ様エフェクターＢ（ＣＩＤＥＢ）ｉＲＮＡ組成物およびその使用方法
|
|
JP2024535850A
(ja)
|
2021-09-17 |
2024-10-02 |
アルナイラム ファーマシューティカルズ， インコーポレイテッド |
補体成分（Ｃ３）をサイレンシングするためのｉＲＮＡ組成物および方法
|
|
JP2024535888A
(ja)
|
2021-09-20 |
2024-10-02 |
アルナイラム ファーマシューティカルズ， インコーポレイテッド |
インヒビンサブユニットベータｅ（ｉｎｈｂｅ）モジュレーター組成物およびその使用方法
|
|
MX2024003519A
(es)
|
2021-09-24 |
2024-04-01 |
Alnylam Pharmaceuticals Inc |
Composiciones de agentes de acido ribonucleico de interferencia (arni) de proteina tau asociada a microtubulos (mapt) y sus metodos de uso.
|
|
KR20240101590A9
(ko)
|
2021-10-15 |
2025-12-10 |
알닐람 파마슈티칼스 인코포레이티드 |
간외 전달 irna 조성물 및 이를 이용하는 방법
|
|
JP2024541974A
(ja)
|
2021-10-29 |
2024-11-13 |
アルナイラム ファーマシューティカルズ， インコーポレイテッド |
ハンチンチン（ＨＴＴ）ｉＲＮＡ剤組成物およびその使用方法
|
|
CA3234636A1
(en)
|
2021-10-29 |
2023-05-04 |
Alnylam Pharmaceuticals, Inc. |
Complement factor b (cfb) irna compositions and methods of use thereof
|
|
WO2023102188A1
(en)
*
|
2021-12-03 |
2023-06-08 |
Quralis Corporation |
Gapmer antisense oligonucleotides with modified backbone chemistries
|
|
EP4469575A2
(en)
|
2022-01-24 |
2024-12-04 |
Alnylam Pharmaceuticals, Inc. |
Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof
|
|
EP4547683A2
(en)
|
2022-06-30 |
2025-05-07 |
Alnylam Pharmaceuticals, Inc. |
Cyclic-disulfide modified phosphate based oligonucleotide prodrugs
|
|
EP4569113A1
(en)
|
2022-09-15 |
2025-06-18 |
Regeneron Pharmaceuticals, Inc. |
17b-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof
|
|
JP2025532985A
(ja)
|
2022-09-30 |
2025-10-03 |
アルナイラム ファーマシューティカルズ， インコーポレイテッド |
修飾二本鎖ｒｎａ剤
|
|
WO2024216155A1
(en)
|
2023-04-12 |
2024-10-17 |
Alnylam Pharmaceuticals, Inc. |
Extrahepatic delivery of double-stranded rna agents
|
|
WO2025034422A1
(en)
|
2023-08-04 |
2025-02-13 |
Alnylam Pharmaceuticals, Inc. |
Methods and compositions for treating ctnnb1-associated disorders
|
|
WO2025064660A2
(en)
|
2023-09-21 |
2025-03-27 |
Alnylam Pharmaceuticals, Inc. |
Activin a receptor type 1c (acvr1c) irna compositions and methods of use thereof
|
|
WO2025076031A2
(en)
|
2023-10-03 |
2025-04-10 |
Alnylam Pharmaceuticals, Inc. |
Peritoneal macrophages comprising a nanoparticle encapsulating a nucleic acid molecule and methods of use thereof
|